Pediatric Implantable Low-Shear Pulsatile Blood Pump with Physiologic Sensing and Control

Information

  • Research Project
  • 9898449
  • ApplicationId
    9898449
  • Core Project Number
    R44HL142432
  • Full Project Number
    5R44HL142432-03
  • Serial Number
    142432
  • FOA Number
    PA-17-302
  • Sub Project Id
  • Project Start Date
    8/6/2018 - 6 years ago
  • Project End Date
    3/31/2021 - 3 years ago
  • Program Officer Name
    EVANS, FRANK
  • Budget Start Date
    4/1/2020 - 4 years ago
  • Budget End Date
    3/31/2021 - 3 years ago
  • Fiscal Year
    2020
  • Support Year
    03
  • Suffix
  • Award Notice Date
    3/25/2020 - 4 years ago

Pediatric Implantable Low-Shear Pulsatile Blood Pump with Physiologic Sensing and Control

Project Summary / Abstract The goal of this project is to develop high-level physiological control, improve low-level dynamic piston control, and develop hemodynamic sensing capabilities for the pediatric TORVADTM, a unique ventricular assist system that delivers low-shear, synchronous, pulsatile flow, using controlled piston motion within a torus-shaped pumping chamber. The pediatric TORVAD is intended for patients with a body surface area from 0.6 to 1.5 m2, but the design can be scaled to adapt to a wide variety of patient sizes and needs. Low shear in the pumped blood is managed by the relatively low speed of the pistons which are supported by hydrodynamic bearings that maintain a fixed piston-torus gap. The primary operating mode delivers a 15 mL counterpulse ejection, but the pump can also operate asynchronously to deliver full cardiac support up to 4 L/min. The system synchronizes with the heart to preserve aortic valve flow and maintains autoregulation of cardiac output by the Frank-Starling mechanism. The design of the TORVAD also enables determination of differential pump pressure, without additional sensors. This inherent sensing capability can be used to inform patient medications and optimal pump support. These device advantages have been confirmed in benchtop studies and acute and chronic animal experiments with an adult TORVAD, and results have indicated preservation of high-molecular-weight von Willebrand Factor. The pediatric TORVAD has been designed to exhibit these same advantages, and thus has the potential to reduce bleeding, thrombus formation, and strokes that are associated with the use of other pediatric ventricular assist devices. Specific aims for Phase I are: (1) Improve the dynamic piston control; (2) Implement dynamic pressure sensing during pump actuation; and (3) Develop systemic vascular resistance (SVR) estimation. Specific aims for Phase II are: (1) Implement physiologic control of VAD flow; (2) Fabricate devices for acute and chronic animal experiments; (3) Perform four acute animal studies to assess control algorithms, pressure signal sensing, and SVR estimation; (4) Perform six chronic animal studies to assess long-term viability of the pediatric TORVAD and algorithms.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R44
  • Administering IC
    HL
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    747718
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
    NHLBI:747718\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    WINDMILL CARDIOVASCULAR SYSTEMS, INC.
  • Organization Department
  • Organization DUNS
    831180000
  • Organization City
    AUSTIN
  • Organization State
    TX
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    787521020
  • Organization District
    UNITED STATES